Evolution of vaginal Candida species recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis: The emergence of Candida glabrata?

Clinical Infectious Diseases

Volumn 28, Issue 5, 1999, Pages 1025-1031

  Vazquez, Jose A ^a   Sobel, Jack D ^b   Peng, Grace ^b   Steele Moore, Lynn ^b   Schuman, Paula ^b   Holloway, William ^b   Neaton, James D ^b  

^a Henry Ford Health System Division of Infectious Diseases   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; FLUCONAZOLE;

ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; FUNGUS CULTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VAGINA CANDIDIASIS;

EID: 0032909565     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/514746     Document Type: Article

References (31)

1. 1. Diamond RD. The growing problem of mycoses in patients infected with the human immunodeficiency virus. Rev Infect Dis 1991;13:480-6.
2. 2. Torssander J, Morfeldt-Manson L, Biberfield G, Karlsson A, Putkonen P, Wasserman J. Oral Candida alhicans in HIV infection. Scand J Infect Dis 1987;19:291-5.
3. 3. Selik RM, Starcher ET, Curran JW. Opportunistic diseases reported in AIDS patients: frequencies, associations, and trends. AIDS 1987;1: 175-82.
4. 4. Klein RS, Harris CA, Small CB, Moll B, Lesser M, Friedland GH. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N Engl J Med 1984;311:354-8.
5. 5. Koletar SL, Russell JA, Fass RJ, Plouffe JF. Comparison of oral fluconazole and clotrimazole troches as treatment for oral candidiasis in patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1990;34:2267-8.
6. 6. Laine L, Dretler RH, Conteas CN, et al. Fluconazole compared with ketoconazole for the treatment of Candida esophagitis in AIDS: a randomized trial. Ann Intern Med 1992;117:655-60.
7. 7. Pons V, Greenspan D, Debruin M. Therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, prospective multicenter study of oral fluconazole versus clotrimazole troches. J Acquir Immune Defic Syndr 1993;6:1311-6.
8. 8. Leen CL, Dunbar EM, Ellis ME, Mandal BK. Once-weekly fluconazole to prevent recurrence of oropharyngeal candidiasis in patients with AIDS and AIDS-related complex: a double-blind-placebo-controlled study. J Infect 1990;21:55-60.
9. 9. Stevens DA, Green SI, Lang OS. Thrush can be prevented in patients with acquired immunodeficiency syndrome and the acquired immunodeficiency syndrome related complex. Randomized, double-blind, placebo-controlled study of 100 mg oral fluconazole daily. Arch Intern Med 1991;151:2458-64.
10. 10. Just-Nubling G, Gentschew C, Meissner K, et al. Fluconazole prophylaxis of recurrent oral candidiasis in HIV-positive patients. Eur J Clin Microbiol Infect Dis 1991;10:917-21.
11. 11. Marriott DJ, Jones PD, Hoy JR, Speed BR, Harness JL. Fluconazole once a week as secondary prophylaxis against oropharyngeal candidiasis in HIV-infected patients. A double-blind placebo-controlled study. Med J Aust 1993;158:312-6.
12. 12. Schuman P, Capps L, Peng G, et al., and the Terry Beirn Community Programs for Clinical Research on AIDS. Weekly fluconazole in the prevention of mucosal candidiasis in women with HIV disease: a randomized, double-blind, placebo controlled study. Ann Intern Med 1997; 126:689-96.
13. 13. Powderly WG, Finkelstein DM, Feinberg J, et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995;332:700-5.
14. 14. Wingard JR, Merz WG, Rinaldi MG, et al. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991; 325:1274-7.
15. 15. Wingard JR, Merz WG, Rinaldi MG, et al. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 1993;37: 1847-9.
16. 16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
17. 17. Cox DR. The analysis of binary data. London: Chapman & Hall, 1970.
18. 18. Wolfinger R, O'Connell M. Generalized linear models: a pseudo-likelihood approach. Journal of Statistical Computer Simulations 1993;48: 233-43.
19. 19. Sangeorzan JA, Bradley SF, Xiaogang HE, et al. Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med 1994;97:339-46.
20. 20. Paugam A, Dupouy-Camet J, Blanche P, Gangneux JP, Tourte-Schaefer C, Sicard D. Increased fluconazole resistance of Cryptococcus neoformans isolated from a patient with AIDS and recurrent meningitis. Clin Infect Dis 1994;19:975-6.
21. 21. Just G, Steinheimer D, Schnellbach B, et al. Change of causative organisms under antifungal treatment in immunosuppressed patients with HIV infections. Mycoses 1989;32(suppl 2):47-51.
22. 22. Ng TTC, Denning DW. Fluconazole resistance in Candida in patients with AIDS: a therapeutic approach. J Infect 1994;26:117-5.
23. 23. Conly J, Rennie R, Johnson J, Farah S, Hellman L. Disseminated candidiasis due to amphotericin B resistant Candida albicans. J Infect Dis 1991;165:761-4.
24. 24. Edwards JE Jr, Bodey GP, Bowden RA, et al. International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin Infect Dis 1997;25:43-59.
25. 25. McCarthy GM, Mackie ID, Koval J, Sandhu HS, Daley TD. Factors associated with increased frequency of HIV-related oral candidiasis. J Oral Pathol Med 1991;20:332-6.
26. 26. Johnson EM, Warnock DW, Luker J, Porter SR, Scully C. Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis. J Antimicrob Chemother 1995;35:103-14.
27. 27. Agabian N, Miyasaki SH, White TC, Moeller TA, Padian N, Greenblatt R. Identification of fungal species present in oral and vaginal sites from women at risk for AIDS [abstract no 1761]. In: Program and abstracts of the American Society for Microbiology Conference on Candida and Tandidosis (San Diego). Washington, DC: American Society for Microbiology, 1994:16.
28. 28. Maenza JR, Merz WG, Romagnoli MJ, Keruly JC, Moore RD, Gallant JE. Infection due to fluconazole-resistant Candida in patients with AIDS: prevalence and microbiology. Clin Infect Dis 1997;24;28-34.
29. 29. Maenza JR, Keruly JC, Moore RD, Chaisson RE, Merz WG, Gallant JE. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus infected patients. J Infect Dis 1996;173:219-25.
30. 30. Sanguineli A, Carmichael JK, Campbell K. Pluconazole-resistant Candida albicans after long-term suppressive therapy. Arch Intern Med 1993; 153:1122-4.
31. 31. Sobel JD. Vaginitis. N Engl J Med 1997;337:1896-903.